FactSet Research Systems Inc. Common Stock (NY:FDS)

279.46 +9.51 (+3.52%)

Delayed Quote Updated: 3:41 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FactSet Research Systems Inc. Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

BMO Capital Maintains Market Perform Rating for FactSet Research Systems: Here's What You Need To Know ↗

June 26, 2023

Via Benzinga

Chipotle To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday ↗

June 23, 2023

Keybanc boosted the price target for Advanced Energy Industries, Inc. (NASDAQ: AEIS) from $105 to $125. Keybanc analyst Steve Barger maintained an Overweight rating. Advanced Energy shares fell 0.6% to...

Via Benzinga

FactSet Research Systems Falls Into The Buy Zone

June 23, 2023

Factset Research Systems had a solid quarter and raised the outlook for earnings, sending shares down more than 5% into a buy zone.

Via MarketBeat

Why FactSet Research Systems Shares Sliding Today ↗

June 22, 2023

FactSet Research Systems Inc. (NYSE: FDS) reported

Via Benzinga

FactSet Research Likely To Report Lower Q3 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts ↗

June 22, 2023

FactSet Research Systems Inc. (NYSE: FDS) is expected to report its financial and operating results for the third quarter fiscal 2023, ending May 31, 2023, before the opening bell on June 22, 2023.

Via Benzinga

FactSet Research Systems Earnings Preview ↗

June 21, 2023

Via Benzinga

Analyst Expectations for FactSet Research Systems's Future ↗

June 15, 2023

Via Benzinga

Why Tesla Is Ending the Week on a High Note ↗

March 31, 2023

Tesla may be looking to invest in yet another battery production plant in the U.S.

Via The Motley Fool

Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 22, 2023

Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private...

Via Benzinga

3 Dividend Stocks Yielding About 5% That Should Continue Growing Their Payouts Through at Least 2025 ↗

June 13, 2023

Analysts expect these companies to produce the growing cash flows needed to support rising dividends.

Via The Motley Fool

Will Chart Analysts Notice Bad Omen on FactSet Research Systems's Chart ↗

March 29, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About FactSet Research Systems ↗

March 24, 2023

Via Benzinga

FactSet Slashes FY23 Topline Outlook After Mixed Q2 Results ↗

March 23, 2023

Via Benzinga

FactSet Research Systems's Earnings Outlook ↗

March 22, 2023

Via Benzinga

3 Dividend Stocks That Should Pay You the Rest of Your Life ↗

June 12, 2023

These stocks raised their dividends annually for at least a decade and should continue rewarding investors for years.

Via The Motley Fool

7 Overvalued Value Stocks to Sell Before June 2023 ↗

May 28, 2023

Eventually, even heavily discounted enterprises lose their charm, transitioning to become overvalued value stocks to sell.

Via InvestorPlace

Microsoft To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

May 23, 2023

Credit Suisse cut the price target for Big Lots, Inc. (NYSE: BIG) from $13 to $7. Credit Suisse analyst Karen Short maintained an Underperform rating. Big Lots shares gained 2.9% to $8.15 in pre-market...

Via Benzinga

FactSet Is Navigating Financial Sector Pressures With Aggressive Pricing And Margin Expansion, Analyst Weighs In ↗

May 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 15, 2023 ↗

May 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023 ↗

May 09, 2023

Via Benzinga

4 Dividend Stocks Yielding 4.5%-Plus That Are Great Buys, According to Wall Street ↗

April 19, 2023

These dividend stocks offer income and upside potential.

Via The Motley Fool

Verisk Stock Ready To Break Out Of Holding Pattern? ↗

March 29, 2023

On Wednesday, the Relative Strength Rating for Verisk stock rose to 74. That put it in the top 26% of stocks for price performance.

Via Investor's Business Daily

These 4 Top Dividend Stocks Have 22% to 47% Upside Potential, According to Wall Street ↗

March 29, 2023

These stocks offer attractive yields and stock price appreciation potential.

Via The Motley Fool

Technical Analysis Of Factset Research Systems Inc. ↗

March 29, 2023

Looking at the FDS chart, we can see it dropped from around $425 to around $385 and now it has been corrected to the lastly traded price of around $401.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗

March 28, 2023

Via Benzinga

Equilar to Provide Real-time Intelligence Through FactSet Signals

March 15, 2023

From Equilar

Via Business Wire

Earnings Scheduled For March 23, 2023 ↗

March 23, 2023

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.

Via Benzinga

3 Resilient Financial Stocks That Can Keep Increasing Earnings ↗

February 21, 2023

These phenomenal companies had earnings growth despite a challenging economic backdrop last year. Here's why they can keep going.

Via The Motley Fool

These 3 Energy Stocks Should Have the Fuel to Continue Paying a Gusher of Dividends ↗

February 11, 2023

These energy companies should generate enough cash to continue paying high-yielding dividends for the next couple of years.

Via The Motley Fool

Our 7 Top Stock Picks From Crossing Wall Street’s 2023 Buy List ↗

February 07, 2023

These unusual stock picks have proved to be consistent winners for investor Eddy Elfenbein, as evidenced by their market beating returns.

Via InvestorPlace

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.